Ann: Corporate Presentation, page-43

Understandable to a degree. The sooner we can get phase 1/2 clinical results for topical application demonstrating safety in humans maybe the sooner hospitals might start seeking emergency access. Surely safety in topical applications coupled with the sinusitis results could open up a whole lot of new tests. Unfortunately the sinusitis case seemed to show that the patient may need to be aware of Rce 327 and specifically request it before the hospital will take action?
There seem to be a few stories about of these untreatable infections. Signs of the growing anti biotic resistance i guess. Ideal chance for Recce to show what it can do if it can get the chance to be used. And many of these infections seem to be life threatening